Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells

Frontiers in Oncology(2021)10.3389/fonc.2021.694793Source: DataRank Database

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells is a research paper published in Frontiers in Oncology (2021). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.38)OA: goldTopics (32)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Ashapurna Sarma,Seongho Kim ORCID,Katherine Gurdziel ORCID,Gen Sheng Wu ORCID,Malathy P.V. Shekhar ORCID

Live enrichment

PubMed:34367977 PMC:PMC8339968 OpenAlex:https://openalex.org/W3185624453

National Institutes of Health

Grant: 3P30CA022453-37S2

Cancer Center Support Grant

National Institutes of Health

Grant: 5R21CA178117-02

Targeting Rad6 Postreplication DNA Repair to Treat Triple Negative Breast Cancer

Barbara Ann Karmanos Cancer Institute

National Institutes of Health

FWCI

1.38

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://doi.org/10.3389/fonc.2021.694793

publisherhttps://doi.org/10.3389/fonc.2021.694793

publisherhttps://www.frontiersin.org/articles/10.3389/fonc.2021.694793/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34367977

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8339968

Fields of Study

PARP inhibition in cancer therapyDNA Repair MechanismsCell death mechanisms and regulation0301 basic medicine03 medical and health sciences

Keywords

OlaparibCisplatinRAD51Cancer researchTriple-negative breast cancerPARP inhibitorDNA repairBiologyDNA damagePoly ADP ribose polymeraseHomologous recombinationSynthetic lethalityCancerMolecular biologyBreast cancerPolymeraseGeneticsDNAChemotherapyBRCA1PARPRna-seqacquired resistanceΓh2ax FociOncologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells

FAIR Checklist

Authors (6)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)